Skip to main content
. Author manuscript; available in PMC: 2015 Jan 1.
Published in final edited form as: J Hepatol. 2013 Aug 23;60(1):160–166. doi: 10.1016/j.jhep.2013.08.015

Fig. 1. Effect of oltipraz on BDL-induced liver injury.

Fig. 1

(A) Representative hematoxylin and eosin images of liver sections from unoperated and BDL mice treated with either CMC or oltipraz (OPZ). Oltipraz treated livers from BDL mice showed extensive hepatic necrosis as indicated by arrows. (B) Immunohistochemical staining for CK19 in livers from CMC-BDL and oltipraz-BDL mice, (original magnification, 4X). (C) Plasma ALT and (D) Biliary bilirubin levels were significantly higher in oltipraz-BDL mice compared to CMC-BDL mice. * p < 0.05; between indicated groups.